I don’t have live access to the latest updates right now. Here’s what I can share based on recent public information up to 2025–2026 and typical outbreak context for Orthoebolavirus zairense (EBOV):
What it is: Orthoebolavirus zairense is the species formerly known as Zaire ebolavirus, a highly pathogenic filovirus that can cause Ebola virus disease (EVD) in humans. It is part of the Ebola virus genus and is transmitted via bodily fluids, contaminated surfaces, and, in some cases, zoonotic spillover, with high mortality in outbreaks when not rapidly treated.[3][5]
Notable recent context: There have been publicized Ebola outbreaks in the Democratic Republic of Congo (DRC) in the 2020s, with health authorities and partners coordinating vaccine and therapeutic responses. For example, press releases in 2025 discuss outbreak investigations in Kasai Province and the deployment of treatments like EBOV-targeted monoclonal antibodies (e.g., Ebanga/Inmazeb) under emergency use or compassionate programs. These developments reflect ongoing international collaboration to contain Orthoebolavirus zairense outbreaks and provide access to approved therapies where allowed.[1][2]
Treatments and vaccines: There are FDA-approved therapies and vaccines for Orthoebolavirus zairense that are deployed in outbreak settings, including monoclonal antibody regimens and vaccines designed to reduce progression and transmission during outbreaks. Agencies and manufacturers have issued supply commitments and compassionate-use programs to affected countries, with safety profiles noted in the product literature for common adverse events such as fever, chills, tachycardia, tachypnea, and GI symptoms.[2]
Outbreak dynamics and risk: Outbreaks of EBOV can vary in size and CFR, and risk mapping and phylogenetic analyses help track lineages and transmission. Peer-reviewed work has examined lineage classification and outbreak relationships to better understand spread and inform response. Spatial risk modeling for orthoebolaviruses remains an active area of research to anticipate spillover and guide public health actions.[5][3]
Public health guidance: Ebola outbreaks trigger standard public health measures: rapid case finding, isolation and supportive care, contact tracing, vaccination campaigns where available, and infection prevention in health facilities. The role of vaccines and therapeutics is complementary to these measures and aims to reduce mortality and transmission.[1][2][5]
If you’d like, I can:
As the high pathogenic species of Filoviridae virus family, Orthoebolavirus zairense (EBOV) shows frequent outbreaks in human in recently years since its first emerging in 1976 in Democratic Republic of the Congo (COD), bringing ongoing risks and burden on public health safety. Here, the phylogeneti …
pubmed.ncbi.nlm.nih.govAbstractBackground. Ebola (EBOV) and Sudan (SUDV) orthoebolaviruses are responsible for lethal hemorrhagic fever outbreaks in humans in Central and West Af
academic.oup.comRecent outbreaks of Marburg virus disease in regions of sub-Saharan Africa without prior record such as Ghana, Tanzania, Equatorial Guinea, and Rwanda challenge the current understanding of areas at-risk for filovirus spillover. The ...
pmc.ncbi.nlm.nih.govWe develop and test a risk map for Orthoebolaviruses which are emerging infectious pathogens primarily concentrated in sub-Saharan Africa. The accuracy of predictive models and risk maps has been limited thus far by uncertainty in mechanisms ...
pmc.ncbi.nlm.nih.govPer CDCKey points • Ebola disease is caused by an infection with an orthoebolavirus. • Orthoebolaviruses are found primarily in sub-Saharan Africa. • Orthoebolaviruses can cause serious and often deadly disease, with a mortality rate as high as 80 to 90 percent. • There is an FDA-approved vaccine for the prevention of Ebola virus (species Orthoebolavirus zairense).TypesThere are four orthoebolaviruses that cause illness in people: • Ebola virus (species Orthoebolavirus zairense) causes Ebola vir
www.bchealthdept.orgOrthoebolavirus zairense es un especie
ecuador.inaturalist.orgspecies of virus
www.wikidata.orgInmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus Supply is being rushed to Democratic Republic of Congo (DRC) to help with the current outbreak
newsroom.regeneron.com/PRNewswire/ -- The Minister of Health from the Democratic Republic of the Congo (DRC) has declared an outbreak of Ebola virus disease (EVD) in Kasai Province...
www.prnewswire.com